1. 1984 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364
2. Wahlberg G, Walldius G 1992 Effects of nicotinic acid treatment on fatty acid composition of plasma lipids and adipose tissue in hyperlipidaemia. Scand J Clin Lab Invest 52:547-553
3. Ehara S, Naruko T, Kobayashi Y, Kataoka T, Nakagawa M, Shirai N, Ishii H, Okuyama T, Oe H, Sugioka K, Hozumi T, Haze K, Yoshikawa J, Yoshiyama M, Ueda M 2007 Comparison of clinical characteristics and arterial remodeling by intravascular ultrasonic imaging in three age groups (< or =55, 56 to 69 and > or =70 years) of Japanese patients with acute myocardial infarction. Am J Cardiol 100:1713-1717
4. Hasegawa T, Ehara S, Kobayashi Y, Kataoka T, Yamashita H, Nishioka H, Asawa K, Yamagishi H, Yoshiyama M, Takeuchi K, Yoshikawa J, Ueda M 2006 Acute myocardial infarction: clinical characteristics and plaque morphology between expansive remodeling and constrictive remodeling by intravascular ultrasound. Am Heart J 151:332-337
5. Centers for Disease Control and Prevention. National Center for Health Statistics, National Vital Statistics System. August 2007. In: http://wwwcdcgov/nchs/nvsshtm
6. Redgrave TG 2004 Chylomicron metabolism. Biochem Soc Trans 32:79-82
7. Griffin BA, Fielding BA 2001 Postprandial lipid handling. Curr Opin Clin Nutr Metab Care 4:93-98
8. Hugh P, Barrett R 1998 Kinetics of triglyceride rich lipoproteins: chylomicrons and very low density lipoproteins. Atherosclerosis 141 Suppl 1:S35-40
9. Hultin M, Olivecrona T 1998 Conversion of chylomicrons into remnants. Atherosclerosis 141 Suppl 1:S25-29
10. Mero N, Syvanne M, Taskinen MR 1998 Postprandial lipid metabolism in diabetes. Atherosclerosis 141 Suppl 1:S53-55
11. van Greevenbroek MM, de Bruin TW 1998 Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 141 Suppl 1:S9-16
12. Williams CM 1998 Dietary interventions affecting chylomicron and chylomicron remnant clearance. Atherosclerosis 141 Suppl 1:S87-92
13. Streja D, Kallai MA, Steiner G 1977 The metabolic heterogeneity of human very low density lipoprotein triglyceride. Metabolism 26:1333-1344
14. Streja DA, Marliss EB, Steiner G 1977 The effects of prolonged fasting on plasma triglyceride kinetics in man. Metabolism 26:505-516
15. Packard CJ, Shepherd J 1997 Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17:3542-3556
16. Demant T, Packard C 1998 In vivo studies of VLDL metabolism and LDL heterogeneity. Eur Heart J 19 Suppl H:H7-10
17. Gibbons GF, Wiggins D, Brown AM, Hebbachi AM 2004 Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 32:59-64
18. Parhofer KG, Barrett PH 2006 Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J Lipid Res 47:1620-1630
19. Brown MS, Kovanen PT, Goldstein JL 1981 Regulation of plasma cholesterol by lipoprotein receptors. Science 212:628-635
20. Brown MS, Goldstein JL 1983 Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261
21. Millar JS, Packard CJ 1998 Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies. Curr Opin Lipidol 9:197-202
22. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ 2002 Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 162:227-244
23. Aviram M 1999 Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins. Antioxid Redox Signal 1:585-594
24. Jessup W, Kritharides L 2000 Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11:473-481
25. Itabe H, Takano T 2000 Oxidized low density lipoprotein: the occurrence and metabolism in circulation and in foam cells. J Atheroscler Thromb 7:123-131
26. Kwiterovich PO, Jr. 1998 The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q-21Q
27. Wierzbicki AS, Mikhailidis DP 2002 Beyond LDL-C--the importance of raising HDL-C. Curr Med Res Opin 18:36-44
28. Fruchart JC, Duriez P 2002 HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 13:605-616
29. Asztalos BF, Schaefer EJ 2003 HDL in atherosclerosis: actor or bystander? Atheroscler Suppl 4:21-29
30. Rosenson RS 2005 Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 118:1067-1077
31. Rader DJ 2007 Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 4:102-109
32. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB, Jr. 2000 Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 11:267-275
33. Jonas A 2000 Lecithin cholesterol acyltransferase. Biochim Biophys Acta 1529:245-256
34. Jin W, Marchadier D, Rader DJ 2002 Lipases and HDL metabolism. Trends Endocrinol Metab 13:174-178
35. Ohashi R, Mu H, Wang X, Yao Q, Chen C 2005 Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 98:845-856
36. Zannis VI, Chroni A, Krieger M 2006 Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 84:276-294
37. Connelly MA, Williams DL 2004 SR-BI and HDL cholesteryl ester metabolism. Endocr Res 30:697-703
38. van der Velde AE, Groen AK 2005 Shifting gears: liver SR-BI drives reverse cholesterol transport in macrophages. J Clin Invest 115:2699-2701
39. Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ 2005 Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 16:307-315
40. Schmitz G, Langmann T 2001 Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol 12:129-140
41. Oram JF, Lawn RM 2001 ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42:1173-1179
42. Brewer HB, Jr., Santamarina-Fojo S 2003 New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol 91:3E-11E
43. Ikonen E, Heino S, Lusa S 2004 Caveolins and membrane cholesterol. Biochem Soc Trans 32:121-123
44. Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G 2004 LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem Soc Trans 32:92-96
45. Forrester JS, Makkar R, Shah PK 2005 Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111:1847-1854
46. Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA 2006 Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 26:706-715
47. Schaefer EJ, Asztalos BF 2006 Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 17:394-398
48. Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G 2003 Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans 31:1070-1074
49. Jansen H 2004 Hepatic lipase: friend or foe and under what circumstances? Curr Atheroscler Rep 6:343-347
50. Cilingiroglu M, Ballantyne C 2004 Endothelial lipase and cholesterol metabolism. Curr Atheroscler Rep 6:126-130
51. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S 2003 Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49:1785-1796
52. Suk Danik J, Rifai N, Buring JE, Ridker PM 2006 Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 296:1363-1370
53. Koschinsky ML, Marcovina SM 2004 Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 15:167-174
54. Mahley RW, Innerarity TL, Rall SC, Jr., Weisgraber KH 1984 Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25:1277-1294
55. Pastier D, Dugue S, Boisfer E, Atger V, Tran NQ, van Tol A, Chapman MJ, Chambaz J, Laplaud PM, Kalopissis AD 2001 Apolipoprotein A-II/A-I ratio is a key determinant in vivo of HDL concentration and formation of pre-beta HDL containing apolipoprotein A-II. Biochemistry 40:12243-12253
56. Tso P, Liu M 2004 Apolipoprotein A-IV, food intake, and obesity. Physiol Behav 83:631-643
57. Pearson K, Tubb MR, Tanaka M, Zhang XQ, Tso P, Weinberg RB, Davidson WS 2005 Specific sequences in the N and C termini of apolipoprotein A-IV modulate its conformation and lipid association. J Biol Chem 280:38576-38582
58. Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC 2006 Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann Med 38:2-10
59. Wong K, Ryan RO 2007 Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol 18:319-324
60. Johs A, Hammel M, Waldner I, May RP, Laggner P, Prassl R 2006 Modular structure of solubilized human apolipoprotein B-100. Low resolution model revealed by small angle neutron scattering. J Biol Chem 281:19732-19739
61. Innerarity TL, Young SG, Poksay KS, Mahley RW, Smith RS, Milne RW, Marcel YL, Weisgraber KH 1987 Structural relationship of human apolipoprotein B48 to apolipoprotein B100. J Clin Invest 80:1794-1798
62. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, Milne R 2000 Apolipoprotein D. Biochim Biophys Acta 1482:185-198
63. Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, Marz W 1998 Molecular basis of type III hyperlipoproteinemia in Germany. Hum Mutat 11:417-423
64. Wang X, Driscoll DM, Morton RE 1999 Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 274:1814-1820
65. de Groot PG, van Lummel M, Pennings M, Urbanus R, Bas de Laat H, Lenting PJ, Derksen RH 2004 Beta2-glycoprotein I and LDL-receptor family members. Thromb Res 114:455-459
66. Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, Frangione B, Ghiso J 1999 Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J 344 Pt 2:375-383
67. Albert TS, Duchateau PN, Deeb SS, Pullinger CR, Cho MH, Heilbron DC, Malloy MJ, Kane JP, Brown BG 2005 Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. J Lipid Res 46:469-474
68. Vanhollebeke B, Pays E 2006 The function of apolipoproteins L. Cell Mol Life Sci 63:1937-1944
69. Dahlback B, Nielsen LB 2006 Apolipoprotein M--a novel player in high-density lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 17:291-295
70. Farwig ZN, McNeal CJ, Little D, Baisden CE, Macfarlane RD 2005 Novel truncated isoforms of constitutive serum amyloid A detected by MALDI mass spectrometry. Biochem Biophys Res Commun 332:352-356
71. de Beer MC, Yuan T, Kindy MS, Asztalos BF, Roheim PS, de Beer FC 1995 Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J Lipid Res 36:526-534
72. Ghandehari H, Kamal-Bahl S, Wong ND 2008 Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 156:112-119
73. Ford ES, Giles WH, Dietz WH 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359
74. Ford ES, Giles WH 2003 A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575-581
75. Ford ES, Giles WH, Mokdad AH 2004 Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 27:2444-2449
76. Ford ES 2005 Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28:2745-2749
77. Thomas GN, Tomlinson B, Hong AW, Hui SS 2006 Age-related anthropometric remodelling resulting in increased and redistributed adiposity is associated with increases in the prevalence of cardiovascular risk factors in Chinese subjects. Diabetes Metab Res Rev 22:72-78
78. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ 1995 Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res 36:1155-1167
79. Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon-Fava S, Asztalos BF, Dolnikowski GG, Brousseau ME, Marsh JB 2004 Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 53:1255-1261
80. Chan DC, Watts GF, Barrett PH 2003 Comparison of intraperitoneal and posterior subcutaneous abdominal adipose tissue compartments as predictors of VLDL apolipoprotein B-100 kinetics in overweight/obese men. Diabetes Obes Metab 5:202-206
81. Pont F, Duvillard L, Florentin E, Gambert P, Verges B 2002 Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 22:1726-1732
82. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ 2004 Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24:1703-1707
83. Ooi EM, Watts GF, Farvid MS, Chan DC, Allen MC, Zilko SR, Barrett PH 2005 High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 13:1008-1016
84. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP, Barrett PH 2006 High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 91:973-979
85. Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ, Marsh JB 2007 Effect of body mass index on apolipoprotein A-I kinetics in middle-aged men and postmenopausal women. Metabolism 56:910-914
86. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R 2005 Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28:690-693
87. Kuhl H 2005 Breast cancer risk in the WHI study: the problem of obesity. Maturitas 51:83-97
88. O'Malley RL, Taneja SS 2006 Obesity and prostate cancer. Can J Urol 13 Suppl 2:11-17
89. Bray GA, Bellanger T 2006 Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29:109-117
90. Cowey S, Hardy RW 2006 The metabolic syndrome: A high-risk state for cancer? Am J Pathol 169:1505-1522
91. Chen Q, Liu Y, Yin Y, Huang W, Li G, Ke D 2007 Relationship between metabolic syndrome (MS) and coronary heart disease (CHD) in an aged group. Arch Gerontol Geriatr
92. Grundy SM 2007 Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92:399-404
93. Burchfiel CM, Shetterly SM, Baxter J, Hamman RF 1992 The roles of insulin, obesity, and fat distribution in the elevation of cardiovascular risk factors in impaired glucose tolerance. The San Luis Valley Diabetes Study. Am J Epidemiol 136:1101-1109
94. Lidfeldt J, Samsioe G, Agardh CD 2006 Obese women and the relation between cardiovascular risk profile and hormone therapy, glucose tolerance, and psychosocial conditions. Diabetes Care 29:2477-2482
95. Burchfiel CM, Abbott RD, Sharp DS, Curb JD, Rodriguez BL, Yano K 1996 Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol 16:1356-1364
96. Yamamoto A, Horibe H, Mabuchi H, Kita T, Matsuzawa Y, Saito Y, Nakaya N, Fujioka T, Tenba H, Kawaguchi A, Nakamura H, Goto Y 1999 Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women. Research Group on Serum Lipid Survey 1990 in Japan. Atherosclerosis 143:55-73
97. Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Fiatarone Singh MA 2004 Anthropometric assessment of 10-y changes in body composition in the elderly. Am J Clin Nutr 80:475-482
98. Imbeault P, Prins JB, Stolic M, Russell AW, O'Moore-Sullivan T, Despres JP, Bouchard C, Tremblay A 2003 Aging per se does not influence glucose homeostasis: in vivo and in vitro evidence. Diabetes Care 26:480-484
99. Tyroler HA, Ford CE 1992 Serum cholesterol and coronary heart disease risk in female and older hypertensives. The experience under usual community care in the Hypertension Detection and Follow-up Program. Ann Epidemiol 2:155-160
100. Hunter GR, Weinsier RL, Gower BA, Wetzstein C 2001 Age-related decrease in resting energy expenditure in sedentary white women: effects of regional differences in lean and fat mass. Am J Clin Nutr 73:333-337
101. Okoro CA, Zhong Y, Ford ES, Balluz LS, Strine TW, Mokdad AH 2006 Association between the metabolic syndrome and its components and gait speed among U.S. adults aged 50 years and older: a cross-sectional analysis. BMC Public Health 6:282
102. Abbott RD, Curb JD, Rodriguez BL, Masaki KH, Yano K, Schatz IJ, Ross GW, Petrovitch H 2002 Age-related changes in risk factor effects on the incidence of coronary heart disease. Ann Epidemiol 12:173-181
103. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Popper J, Chen R, Petrovitch H, Blanchette P, Schatz I, Yano K 2004 Prospective association between low and high total and low-density lipoprotein cholesterol and coronary heart disease in elderly men. J Am Geriatr Soc 52:1975-1980
104. Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, Dalla Vestra M, Previato L, Guido M, Pigozzo S, Cortella I, Crepaldi G, Franceschi C 1998 Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 12:433-437
105. Karlamangla AS, Singer BH, Reuben DB, Seeman TE 2004 Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functioning older adults: MacArthur studies of successful aging. J Am Geriatr Soc 52:487-494
106. 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
107. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC, Jr., Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK 2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 49:1230-1250
108. Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, Hunink MG, Witteman JC 2007 Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J 154:87-93
109. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J 2009 Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338:a3083
110. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR 1992 Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 2:161-176
111. Higgins M, Keller JB 1992 Cholesterol, coronary heart disease, and total mortality in middle-aged and elderly men and women in Tecumseh. Ann Epidemiol 2:69-76
112. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF 1994 Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 272:1335-1340
113. Barrett-Connor E 1992 Hypercholesterolemia predicts early death from coronary heart disease in elderly men but not women. The Rancho Bernardo Study. Ann Epidemiol 2:77-83
114. Anum EA, Adera T 2004 Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol 14:705-721
115. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R 2005 Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 53:219-226
116. Casiglia E, Mazza A, Tikhonoff V, Scarpa R, Schiavon L, Pessina AC 2003 Total cholesterol and mortality in the elderly. J Intern Med 254:353-362
117. Blaum CS, Xue QL, Michelon E, Semba RD, Fried LP 2005 The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. J Am Geriatr Soc 53:927-934
118. Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, Havlik RJ 1997 Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 126:753-760
119. Stewart R, White LR, Xue QL, Launer LJ 2007 Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 64:103-107
120. Panza F, D'Introno A, Colacicco AM, Capurso C, Parigi AD, Capurso SA, Caselli RJ, Pilotto A, Scafato E, Capurso A, Solfrizzi V 2006 Cognitive frailty: Predementia syndrome and vascular risk factors. Neurobiol Aging 27:933-940
121. Lewington S, Thomsen T, Davidsen M, Sherliker P, Clarke R 2003 Regression dilution bias in blood total and high-density lipoprotein cholesterol and blood pressure in the Glostrup and Framingham prospective studies. J Cardiovasc Risk 10:143-148
122. Emberson JR, Whincup PH, Morris RW, Walker M 2003 Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 24:1719-1726
123. Lloyd-Jones DM, Wilson PW, Larson MG, Leip E, Beiser A, D'Agostino RB, Cleeman JI, Levy D 2003 Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 163:1966-1972
124. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D 2006 Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113:791-798
125. Hakim AA, Curb JD, Burchfiel CM, Rodriguez BL, Sharp DS, Yano K, Abbott RD 1999 Screening for coronary heart disease in elderly men based on current and past cholesterol levels. J Clin Epidemiol 52:1257-1265
126. Pencina MJ, D'Agostino RB, Sr., Larson MG, Massaro JM, Vasan RS 2009 Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 119:3078-3084
127. Barrett-Connor E, Bergstrom J, Wright M, Kramer CK 2009 Heart disease risk factors in midlife predict subclinical coronary atherosclerosis more than 25 years later in survivors without clinical heart disease: the Rancho Bernardo Study. J Am Geriatr Soc 57:1041-1044
128. 1995 Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346:1647-1653
129. Schulz UG, Rothwell PM 2003 Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34:2050-2059
130. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD 1989 Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910
131. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD 2002 Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke 33:230-236
132. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G 2006 Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 333:22
133. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A 2006 Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113:2623-2629
134. Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M 2003 Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 26:1241-1245
135. Horiuchi H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H 2004 Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial. J Am Geriatr Soc 52:1981-1987
136. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V 2007 Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450-458
137. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M 2004 Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678-2686
138. Mazza A, Tikhonoff V, Schiavon L, Casiglia E 2005 Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J 35:604-610
139. Barter P 2004 HDL: a recipe for longevity. Atheroscler Suppl 5:25-31
140. Arai Y, Hirose N 2004 Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 11:246-252
141. Terry DF, Evans JC, Pencina MJ, Murabito JM, Vasan RS, Wolf PA, Kelly-Hayes M, Levy D, D'Agostino RB, Sr., Benjamin EJ 2007 Characteristics of Framingham offspring participants with long-lived parents. Arch Intern Med 167:438-444
142. Heijmans BT, Beekman M, Houwing-Duistermaat JJ, Cobain MR, Powell J, Blauw GJ, van der Ouderaa F, Westendorp RG, Slagboom PE 2006 Lipoprotein particle profiles mark familial and sporadic human longevity. PLoS Med 3:e495
143. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, Lumley T, Robbins J, Burke G, Newman AB, Furberg CD 2004 The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 52:1639-1647
144. Curb JD, Abbott RD, Rodriguez BL, Masaki KH, Chen R, Popper JS, Petrovitch H, Ross GW, Schatz IJ, Belleau GC, Yano K 2004 High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. Am J Epidemiol 160:150-157
145. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG 2003 High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 163:1549-1554
146. Zuliani G, Volpatol S, Romagnoni F, Soattin L, Bollini C, Leoci V, Fellin R 2004 Combined measurement of serum albumin and high-density lipoprotein cholesterol strongly predicts mortality in frail older nursing-home residents. Aging Clin Exp Res 16:472-475
147. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG 2005 Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112:3058-3065
148. Bruno G, Merletti F, Biggeri A, Bargero G, Prina-Cerai S, Pagano G, Cavallo-Perin P 2006 Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study. Diabetologia 49:937-944
149. Florvall G, Basu S, Larsson A 2006 Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 61:1262-1266
150. Mooijaart SP, Berbee JF, van Heemst D, Havekes LM, de Craen AJ, Slagboom PE, Rensen PC, Westendorp RG 2006 ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3:e176
151. Ariyo AA, Thach C, Tracy R 2003 Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349:2108-2115
152. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, Simonsick EM, Colbert LH, Kritchevsky SB 2003 Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 23:1444-1448
153. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB 2004 The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53:1068-1073
154. Fletcher AE, Breeze E, Shetty PS 2003 Antioxidant vitamins and mortality in older persons: findings from the nutrition add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Am J Clin Nutr 78:999-1010
155. Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K 2006 Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. J Epidemiol 16:154-160
156. Buijsse B, Feskens EJ, Schlettwein-Gsell D, Ferry M, Kok FJ, Kromhout D, de Groot LC 2005 Plasma carotene and alpha-tocopherol in relation to 10-y all-cause and cause-specific mortality in European elderly: the Survey in Europe on Nutrition and the Elderly, a Concerted Action (SENECA). Am J Clin Nutr 82:879-886
157. Cook NR, Buring JE, Ridker PM 2006 The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21-29
158. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR 2008 C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118:2243-2251, 2244p following 2251
159. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP 2005 C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112:25-31
160. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS 2006 Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631-2639
161. Lehtimaki T, Ojala P, Rontu R, Goebeler S, Karhunen PJ, Jylha M, Mattila K, Metso S, Jokela H, Nikkila M, Wuolijoki E, Hervonen A, Hurme M 2005 Interleukin-6 modulates plasma cholesterol and C-reactive protein concentrations in nonagenarians. J Am Geriatr Soc 53:1552-1558
162. Jenny NS, Yanez ND, Psaty BM, Kuller LH, Hirsch CH, Tracy RP 2007 Inflammation biomarkers and near-term death in older men. Am J Epidemiol 165:684-695
163. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M 2007 Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 5:1128-1135
164. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M 2003 C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108:166-170
165. Hu FB, Stampfer MJ 1999 Nut consumption and risk of coronary heart disease: a review of epidemiologic evidence. Curr Atheroscler Rep 1:204-209
166. Lemaitre RN, King IB, Mozaffarian D, Sotoodehnia N, Rea TD, Kuller LH, Tracy RP, Siscovick DS 2006 Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults: the cardiovascular health study. Circulation 114:209-215
167. Hu FB, Leitzmann MF, Stampfer MJ, Colditz GA, Willett WC, Rimm EB 2001 Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med 161:1542-1548
168. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE 2003 Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 289:1785-1791
169. Virtanen JK, Voutilainen S, Rissanen TH, Mursu J, Tuomainen TP, Korhonen MJ, Valkonen VP, Seppanen K, Laukkanen JA, Salonen JT 2005 Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler Thromb Vasc Biol 25:228-233
170. Mozaffarian D, Rimm EB 2006 Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296:1885-1899
171. Gotto Jr AM, Jr., Farmer JA 2001 Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 12:391-394
172. Liao JK, Laufs U 2005 Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118
173. Arnaud C, Mach F 2005 Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98:661-666
174. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP 2009 Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 15:479-489
175. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S 2001 Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933-1935
176. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E 2005 Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45:1644-1648
177. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E 2005 C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28
178. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P 2005 Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29-38
179. Jones P, Kafonek S, Laurora I, Hunninghake D 1998 Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587
180. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152-160
181. Chinetti-Gbaguidi G, Fruchart JC, Staels B 2005 Pleiotropic effects of fibrates. Curr Atheroscler Rep 7:396-401
182. Robillard R, Fontaine C, Chinetti G, Fruchart JC, Staels B 2005 Fibrates. Handb Exp Pharmacol:389-406
183. Insua A, Massari F, Rodriguez Moncalvo JJ, Ruben Zanchetta J, Insua AM 2002 Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 8:96-101
184. Westphal S, Dierkes J, Luley C 2001 Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:39-40
185. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A 2002 Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92:536-541
186. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 33:215-220
187. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554
188. Nissen SE, Wolski K, Topol EJ 2005 Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294:2581-2586
189. Bays H, Stein EA 2003 Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother 4:1901-1938
190. Kamanna VS, Kashyap ML 2000 Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2:36-46
191. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML 2004 Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45:1835-1845
192. Meyers CD, Liu P, Kamanna VS, Kashyap ML 2007 Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis 192:253-258
193. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ 2008 Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 51:37-45
194. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A 2007 The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 63:113-121
195. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
196. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK 2006 Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166:2307-2313
197. 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
198. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ 2004 Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998. Atheroscler Suppl 5:99-106
199. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E 2004 Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307-1316
200. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
201. 2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007
202. Koren MJ, Hunninghake DB 2004 Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44:1772-1779
203. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
204. Knopp RH, d'Emden M, Smilde JG, Pocock SJ 2006 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29:1478-1485
205. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
206. Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA 2006 Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 29:2378-2384
207. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009
208. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG 2002 Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18:220-228
209. 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
210. Collins R, Armitage J, Parish S, Sleigh P, Peto R 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
211. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445
212. 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357
213. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A 2001 Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 134:931-940
214. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
215. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175-1182
216. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B 2002 Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287:3215-3222
217. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y 2006 Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155-1163
218. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T 2001 Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711-1718
219. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T 2002 Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106:1690-1695
220. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A 2006 Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97:1165-1171
221. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C 2000 Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 102:157-165
222. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
223. Mungall MM, Gaw A, Shepherd J 2003 Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 20:263-275
224. Tolmie EP, Mungall MM, Louden G, Lindsay GM, Gaw A 2004 Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participants. Age Ageing 33:374-378
225. ten Dam VH, van den Heuvel DM, van Buchem MA, Westendorp RG, Bollen EL, Ford I, de Craen AJ, Blauw GJ 2005 Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 64:1807-1809
226. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504
227. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D 2007 Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115:700-707
228. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435
229. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM, Jr., Carter R, Breazna A, Kastelein JJ, Grundy SM 2006 Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 48:1793-1799
230. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK 2007 Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115:576-583
231. 1997 Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. Am J Cardiol 79:756-762
232. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
233. 1996 West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348:1339-1342
234. 1998 Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445
235. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 152:488-496, W174
236. Roberts CG, Guallar E, Rodriguez A 2007 Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 62:879-887
237. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170:1024-1031
238. Ridker PM 2003 Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108:2292-2297
239. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM, Jr. 2001 Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965
240. Segura J, Ruilope LM 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:26; author reply 26-27
241. Goldstein MR, Mascitelli L, Pezzetta F Rosuvastatin and vitamin D: Might there be hypovitaminosis D on JUPITER? Int J Cardiol
242. Bloom JM 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:25-26; author reply 26-27
243. Rosenstein R, Parra D 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:25; author reply 26-27
244. de Tena JG 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:24; author reply 26-27
245. Sniderman AD 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:25; author reply 26-27
246. de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 170:1032-1036
247. Green LA Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med 170:1007-1008
248. Mascitelli L, Goldstein MR, Pezzetta F Earth to JUPITER: how a potent statin may actually be detrimental for lifestyle-associated diseases. Angiology 61:119
249. Accad M, Fred HL Is Jupiter also a god of primary prevention? Tex Heart Inst J 37:6-7
250. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM 2009 Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32:1924-1929
251. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A 2001 Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362
252. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ 2009 Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2:616-623
253. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schunemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303:1180-1187
254. Kaul S, Morrissey RP, Diamond GA By Jove! What is a clinician to make of JUPITER? Arch Intern Med 170:1073-1077
255. rosuvastatin ACmf 15 December 2008, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831.pdf.
.
256. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Jr., Taylor AJ, Weintraub WS, Wenger NK 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation
257. Ridker PM, Glynn RJ JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 375:2071
258. Danchin N 2009 Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. Lancet 374:24-25; author reply 26-27
259. Bajpai A, Goyal A, Sperling L Should we measure C-reactive protein on earth or just on JUPITER? Clin Cardiol 33:190-198
260. Shishehbor MH, Hazen SL 2009 Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleve Clin J Med 76:37-44
261. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132-140
262. Rodondi N, Marques-Vidal P, Butler J, Sutton-Tyrrell K, Cornuz J, Satterfield S, Harris T, Bauer DC, Ferrucci L, Vittinghoff E, Newman AB Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol 171:540-549
263. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, Smeeth L, Deanfield JE, Lowe GD, Rumley A, Fowkes FG, Humphries SE, Hingorani AD 2009 Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38:217-231
264. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R, Sr., O'Donnell CJ 2008 C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 1:92-97
265. Clarke R, Emberson JR, Breeze E, Casas JP, Parish S, Hingorani AD, Fletcher A, Collins R, Smeeth L 2008 Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J 29:800-809
266. Stork S, Feelders RA, van den Beld AW, Steyerberg EW, Savelkoul HF, Lamberts SW, Grobbee DE, Bots ML 2006 Prediction of mortality risk in the elderly. Am J Med 119:519-525
267. Kubo T, Matsuo Y, Hayashi Y, Yamano T, Tanimoto T, Ino Y, Kitabata H, Takarada S, Hirata K, Tanaka A, Nakamura N, Mizukoshi M, Imanishi T, Akasaka T 2009 High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study. Coron Artery Dis 20:531-535
268. Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, Monti D, Franceschi C 2008 Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 15:224-240
269. Shodell M, Siegal FP 2002 Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing. Scand J Immunol 56:518-521
270. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, Ortolani C, Forti E, et al. 1993 Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82:2767-2773
271. Zanni F, Vescovini R, Biasini C, Fagnoni F, Zanlari L, Telera A, Di Pede P, Passeri G, Pedrazzoni M, Passeri M, Franceschi C, Sansoni P 2003 Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol 38:981-987
272. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G 2000 Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244-254
273. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R 1993 Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 23:2375-2378
274. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA 1998 Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 53:M20-26
275. Conroy S 2009 Editorial: Defining Frailty - The Holy Grail of Geriatric Medicine. J Nutr Health Aging 13:389
276. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA 2001 Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-156
277. Kulminski AM, Ukraintseva SV, Kulminskaya IV, Arbeev KG, Land K, Yashin AI 2008 Cumulative deficits better characterize susceptibility to death in elderly people than phenotypic frailty: lessons from the Cardiovascular Health Study. J Am Geriatr Soc 56:898-903
278. Leng S, Chaves P, Koenig K, Walston J 2002 Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 50:1268-1271
279. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK 2003 Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 132:24-31
280. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, Pedersen BK, Jeune B 2003 Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med 115:278-283
281. Tracy RP 2003 Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord 27 Suppl 3:S29-34
282. De Martinis M, Franceschi C, Monti D, Ginaldi L 2006 Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 80:219-227
283. Leng SX, Hung W, Cappola AR, Yu Q, Xue QL, Fried LP 2009 White blood cell counts, insulin-like growth factor-1 levels, and frailty in community-dwelling older women. J Gerontol A Biol Sci Med Sci 64:499-502
284. Leng SX, Xue QL, Tian J, Walston JD, Fried LP 2007 Inflammation and frailty in older women. J Am Geriatr Soc 55:864-871
285. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW 2008 Nutrition, inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc 56:279-284
286. Hubbard RE, O'Mahony MS, Savva GM, Calver BL, Woodhouse KW 2009 Inflammation and frailty measures in older people. J Cell Mol Med
287. Kanapuru B, Ershler WB 2009 Inflammation, coagulation, and the pathway to frailty. Am J Med 122:605-613
288. Lee JS, Kritchevsky SB, Tylavsky F, Harris TB, Ayonayon HN, Newman AB 2006 Factors associated with impaired appetite in well-functioning community-dwelling older adults. J Nutr Elder 26:27-43
289. Vanitallie TB 2003 Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism 52:22-26
290. Ble A, Cherubini A, Volpato S, Bartali B, Walston JD, Windham BG, Bandinelli S, Lauretani F, Guralnik JM, Ferrucci L 2006 Lower plasma vitamin E levels are associated with the frailty syndrome: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 61:278-283
291. Semba RD, Bartali B, Zhou J, Blaum C, Ko CW, Fried LP 2006 Low serum micronutrient concentrations predict frailty among older women living in the community. J Gerontol A Biol Sci Med Sci 61:594-599
292. Michelon E, Blaum C, Semba RD, Xue QL, Ricks MO, Fried LP 2006 Vitamin and carotenoid status in older women: associations with the frailty syndrome. J Gerontol A Biol Sci Med Sci 61:600-607
293. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P 2006 Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 84:616-622; quiz 671-612
294. Matteini AM, Walston JD, Fallin MD, Bandeen-Roche K, Kao WH, Semba RD, Allen RH, Guralnik J, Fried LP, Stabler SP 2008 Markers of B-vitamin deficiency and frailty in older women. J Nutr Health Aging 12:303-308
295. Shardell M, Hicks GE, Miller RR, Kritchevsky S, Andersen D, Bandinelli S, Cherubini A, Ferrucci L 2009 Association of low vitamin D levels with the frailty syndrome in men and women. J Gerontol A Biol Sci Med Sci 64:69-75
296. Lamberts SW, van den Beld AW, van der Lely AJ 1997 The endocrinology of aging. Science 278:419-424
297. Maggio M, Cappola AR, Ceda GP, Basaria S, Chia CW, Valenti G, Ferrucci L 2005 The hormonal pathway to frailty in older men. J Endocrinol Invest 28:15-19
298. Bylow K, Mohile SG, Stadler WM, Dale W 2007 Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 110:2604-2613
299. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP 2002 Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 162:2333-2341
300. Cohen HJ, Harris T, Pieper CF 2003 Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180-187
301. Reiner AP, Aragaki AK, Gray SL, Wactawski-Wende J, Cauley JA, Cochrane BB, Kooperberg CL, Woods NF, Lacroix AZ 2009 Inflammation and Thrombosis Biomarkers and Incident Frailty in Postmenopausal Women. Am J Med
302. Shlipak MG, Stehman-Breen C, Fried LF, Song X, Siscovick D, Fried LP, Psaty BM, Newman AB 2004 The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 43:861-867
303. Wilhelm-Leen ER, Hall YN, Tamura MK, Chertow GM 2009 Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med 122:664-671 e662
304. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Vaananen HK, Obrant KJ, Akesson K 2007 Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 22:127-134
305. Moulias R, Meaume S, Raynaud-Simon A 1999 Sarcopenia, hypermetabolism, and aging. Z Gerontol Geriatr 32:425-432
306. Rolland Y, Lauwers-Cances V, Cournot M, Nourhashemi F, Reynish W, Riviere D, Vellas B, Grandjean H 2003 Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study. J Am Geriatr Soc 51:1120-1124
307. Sergi G, Coin A, Bussolotto M, Beninca P, Tomasi G, Pisent C, Peruzza S, Inelmen EM, Enzi G 2002 Influence of fat-free mass and functional status on resting energy expenditure in underweight elders. J Gerontol A Biol Sci Med Sci 57:M302-307
308. Iwasa H, Yoshida Y, Kumagai S, Ihara K, Yoshida H, Suzuki T 2009 Depression status as a reliable predictor of functional decline among Japanese community-dwelling older adults: a 12-year population-based prospective cohort study. Int J Geriatr Psychiatry
309. Hybels CF, Pieper CF, Blazer DG 2009 The complex relationship between depressive symptoms and functional limitations in community-dwelling older adults: the impact of subthreshold depression. Psychol Med 39:1677-1688
310. Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA 2007 Frailty is associated with incident Alzheimer's disease and cognitive decline in the elderly. Psychosom Med 69:483-489
311. Buchman AS, Schneider JA, Leurgans S, Bennett DA 2008 Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology 71:499-504
312. Avila-Funes JA, Amieva H, Barberger-Gateau P, Le Goff M, Raoux N, Ritchie K, Carriere I, Tavernier B, Tzourio C, Gutierrez-Robledo LM, Dartigues JF 2009 Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 57:453-461
313. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx B, Pahor M, Wallace R, Havlik RJ 1999 Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47:639-646
314. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP 2003 Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 88:2019-2025
315. Penninx BW, Kritchevsky SB, Newman AB, Nicklas BJ, Simonsick EM, Rubin S, Nevitt M, Visser M, Harris T, Pahor M 2004 Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 52:1105-1113
316. Puts MT, Visser M, Twisk JW, Deeg DJ, Lips P 2005 Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf) 63:403-411
317. Schaap LA, Pluijm SM, Deeg DJ, Visser M 2006 Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 119:526 e529-517
318. Stenholm S, Maggio M, Lauretani F, Bandinelli S, Ceda GP, Di Iorio A, Giallauria F, Guralnik JM, Ferrucci L Anabolic and catabolic biomarkers as predictors of muscle strength decline: the InCHIANTI study. Rejuvenation Res 13:3-11
319. Figaro MK, Kritchevsky SB, Resnick HE, Shorr RI, Butler J, Shintani A, Penninx BW, Simonsick EM, Goodpaster BH, Newman AB, Schwartz AV, Harris TB 2006 Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care 29:2039-2045
320. Miller RR, Cappola AR, Shardell MD, Hawkes WG, Yu-Yahiro JA, Hebel JR, Magaziner J 2006 Persistent changes in interleukin-6 and lower extremity function following hip fracture. J Gerontol A Biol Sci Med Sci 61:1053-1058
321. de Saint-Hubert M, Jamart J, Morrhaye G, Martens HJ, Geenen V, Vo TK, Toussaint O, Swine C Serum Il-6 and IGF-1 improve the clinical prediction of functional decline after hospitalization in older patients. Aging Clin Exp Res
322. Boxer RS, Dauser DA, Walsh SJ, Hager WD, Kenny AM 2008 The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J Am Geriatr Soc 56:454-461
323. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F 2005 Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4:371-380
324. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Penttila IM, Helkala EL, Gylling H, Nissinen A, Rauramaa R 2007 Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing 36:443-448
325. Maas DW, van der Mast RC, de Craen AJ 2009 Increased C-reactive protein is not associated with apathy: the Leiden 85-Plus Study. Int J Geriatr Psychiatry 24:1177-1184
326. Hoth KF, Haley AP, Gunstad J, Paul RH, Poppas A, Jefferson AL, Tate DF, Ono M, Jerskey BA, Cohen RA 2008 Elevated C-reactive protein is related to cognitive decline in older adults with cardiovascular disease. J Am Geriatr Soc 56:1898-1903
327. Luukinen H, Jokelainen J, Hedberg P The relationships between high-sensitivity C-reactive protein and incident depressed mood among older adults. Scand J Clin Lab Invest 70:75-79
328. van Vliet P, Westendorp RG, van Heemst D, de Craen AJ, Oleksik AM Cognitive decline precedes late-life longitudinal changes in vascular risk factors. J Neurol Neurosurg Psychiatry 81:1028-1032
329. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiol Aging 31:1700-1709
330. Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, Pessina AC, Staessen JA 2005 Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc 53:2159-2164
331. Schalk BW, Visser M, Deeg DJ, Bouter LM 2004 Lower levels of serum albumin and total cholesterol and future decline in functional performance in older persons: the Longitudinal Aging Study Amsterdam. Age Ageing 33:266-272
332. Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, Kita Y, Abbott RD, Okayama A, Ueshima H 2008 Lower levels of serum albumin and total cholesterol associated with decline in activities of daily living and excess mortality in a 12-year cohort study of elderly Japanese. J Am Geriatr Soc 56:529-535
333. Reuben DB, Ix JH, Greendale GA, Seeman TE 1999 The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc 47:402-406
334. Hrnciarikova D, Hyspler R, Vyroubal P, Klemera P, Hronek M, Zadak Z 2009 Serum lipids and neopterin in urine as new biomarkers of malnutrition and inflammation in the elderly. Nutrition 25:303-308
335. Brescianini S, Maggi S, Farchi G, Mariotti S, Di Carlo A, Baldereschi M, Inzitari D 2003 Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc 51:991-996
336. Spada RS, Toscano G, Cosentino FI, Iero I, Lanuzza B, Tripodi M, Ferri R 2007 Low total cholesterol predicts mortality in the nondemented oldest old. Arch Gerontol Geriatr 44 Suppl 1:381-384
337. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP 2007 Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med 167:635-641
338. Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci 65:377-381
339. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M 2005 Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 82:428-434
340. Goulet ED, Hassaine A, Dionne IJ, Gaudreau P, Khalil A, Fulop T, Shatenstein B, Tessier D, Morais JA 2009 Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat. Exp Gerontol 44:740-744
341. Barzilay JI, Cotsonis GA, Walston J, Schwartz AV, Satterfield S, Miljkovic I, Harris TB 2009 Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged >or=70 years. Diabetes Care 32:736-738
342. Vischer UM, Safar ME, Safar H, Iaria P, Le Dudal K, Henry O, Herrmann FR, Ducimetiere P, Blacher J 2009 Cardiometabolic determinants of mortality in a geriatric population: is there a "reverse metabolic syndrome"? Diabetes Metab 35:108-114
343. Kalantar-Zadeh K, Kopple JD 2006 Body mass index and risk for end-stage renal disease. Ann Intern Med 144:701; author reply 701-702
344. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S 2005 Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46:489-500
345. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE 2006 Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 21:1257-1262
346. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K 2007 A1C and survival in maintenance hemodialysis patients. Diabetes Care 30:1049-1055
347. Kovesdy CP, Anderson JE, Kalantar-Zadeh K 2007 Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 18:304-311
348. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC 2004 Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43:1439-1444
349. Iribarren C, Jacobs DR, Jr., Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H 1997 Serum total cholesterol and risk of hospitalization, and death from respiratory disease. Int J Epidemiol 26:1191-1202
350. Escalante A, Haas RW, del Rincon I 2005 Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624-1629
351. Eisenstaedt R, Penninx BW, Woodman RC 2006 Anemia in the elderly: current understanding and emerging concepts. Blood Rev 20:213-226
352. McMurtry CT, Rosenthal A 1995 Predictors of 2-year mortality among older male veterans on a geriatric rehabilitation unit. J Am Geriatr Soc 43:1123-1126
353. Chen JS, Sambrook PN, March L, Cameron ID, Cumming RG, Simpson JM, Seibel MJ 2008 Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol (Oxf) 68:290-298
354. Kalantar-Zadeh K, Kovesdy CP 2009 Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 4:1529-1539
355. Moe SM 2007 Vitamin D, cardiovascular disease, and survival in dialysis patients. J Bone Miner Res 22 Suppl 2:V95-99
356. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR 2006 Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351-357
357. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J 2002 Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39:1780-1786
358. Alexandersen P, Tanko LB, Bagger YZ, Jespersen J, Skouby SO, Christiansen C 2006 Associations between aortic calcification and components of body composition in elderly men. Obesity (Silver Spring) 14:1571-1578
359. Corsonello A, Garasto S, Abbatecola AM, Rose G, Passarino G, Mazzei B, Pranno L, Guffanti EE, Bustacchini S, Lattanzio F Targeting inflammation to slow or delay functional decline: where are we? Biogerontology 11:603-614
360. Scott D, Blizzard L, Fell J, Jones G 2009 Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 102:625-633
361. Michos ED, Blumenthal RS 2009 Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 53:931-935
362. Spatz ES, Canavan ME, Desai MM 2009 From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2:41-48
363. Kappagoda CT, Amsterdam EA 2009 Another look at the results of the JUPITER trial. Am J Cardiol 104:1603-1605
364. Sposito AC, Alvarenga BF, Alexandre AS, Araujo AL, Santos SN, Andrade JM, Ramires JA, Quinaglia ESJC, Coelho OR Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. Atherosclerosis
365. Parker MS, Hui FK, Camacho MA, Chung JK, Broga DW, Sethi NN 2005 Female breast radiation exposure during CT pulmonary angiography. AJR Am J Roentgenol 185:1228-1233
366. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS 2007 Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 49:1860-1870
367. Raggi P, Gongora MC, Gopal A, Callister TQ, Budoff M, Shaw LJ 2008 Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol 52:17-23
368. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA 2008 Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358:1336-1345
369. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, Greenland P Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 303:1610-1616
370. Elias-Smale SE, Proenca RV, Koller MT, Kavousi M, van Rooij FJ, Hunink MG, Steyerberg EW, Hofman A, Oudkerk M, Witteman JC Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol 56:1407-1414
371. Abbott RD, Ueshima H, Masaki KH, Willcox BJ, Rodriguez BL, Ikeda A, Yano K, White LR, Curb JD 2007 Coronary artery calcification and total mortality in elderly men. J Am Geriatr Soc 55:1948-1954
372. Rodondi N, Taylor BC, Bauer DC, Lui LY, Vogt MT, Fink HA, Browner WS, Cummings SR, Ensrud KE 2007 Association between aortic calcification and total and cardiovascular mortality in older women. J Intern Med 261:238-244
373. Inzitari M, Naydeck BL, Newman AB 2008 Coronary artery calcium and physical function in older adults: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 63:1112-1118
374. Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ 2001 C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J 141:206-210
375. Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, Szklo M, Herrington DM, Jacobs DR, Jr. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 209:226-229
376. Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, Callister T, Raggi P, Blumenthal RS, Nasir K 2009 Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging 2:692-700
377. Blaha M, Budoff, MJ, Defilippis, AP, Rivera, JJ, Blankstein, R, O'Leary, DH, Lima, J, Blumenthal, RS, Nasir, K. 2010 Association between hsCRP2, Coronary Artery Calcium, and Adverse Events - Implications for the JUPITER Population: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 122:A12825
378. Nicholls SJ, Tuzcu EM, Wolski K, Sipahi I, Schoenhagen P, Crowe T, Kapadia SR, Hazen SL, Nissen SE 2007 Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol 49:263-270
379. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD 2005 Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 46:166-172
380. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA 2005 A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352:2389-2397
381. Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, Newby DE 2006 Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart 92:1207-1212
382. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Forster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R 2006 Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 113:427-437
383. Raggi P, Callister TQ, Davidson M, Welty FK, Bachmann GA, Laskey R, Pittman D, Kafonek S, Scott R 2001 Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 141:722-726
384. Raggi P, Davidson M, Callister TQ, Welty FK, Bachmann GA, Hecht H, Rumberger JA 2005 Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 112:563-571
385. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R 2008 Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343-1356
386. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C 2008 Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74:1461-1467
387. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F 2009 Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407
388. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J 2007 Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261
389. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G 2008 Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231-1239
390. Aronow WS, Nayak D, Woodworth S, Ahn C 2003 Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 92:711-712
391. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, Pastore M, Borrello F, Belcastro M, Picchi A, Nami R 2003 Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114:359-364
392. Mohler ER, 3rd, Hiatt WR, Creager MA 2003 Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481-1486
393. Grodzinska L, Starzyk D, Bieron K, Goszcz A, Korbut R 2005 Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. Basic Clin Pharmacol Toxicol 96:413-419
394. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, Taylor L, Chan C, Sharma L, Schneider JR, Ridker PM, Green D, Quann M 2003 Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107:757-761
395. Merla R, Daher IN, Ye Y, Uretsky BF, Birnbaum Y 2007 Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 154:391-402
396. Powell BD, Bybee KA, Valeti U, Thomas RJ, Kopecky SL, Mullany CJ, Wright RS 2007 Influence of preoperative lipid-lowering therapy on postoperative outcome in patients undergoing coronary artery bypass grafting. Am J Cardiol 99:785-789
397. Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD 2007 Renoprotective Effect of Preoperative Statins in Coronary Artery Bypass Grafting. Am J Cardiol 100:442-444
398. Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fleron MH, Riou B 2007 The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 104:1326-1333, table of contents
399. Coleman CI, Lucek DM, Hammond J, Michael C 2007 Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin
400. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Bonizzoni E, Ricciardelli B 2004 Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 25:1822-1828
401. Kapoor AS, Kanji H, Buckingham J, Devereaux PJ, McAlister FA 2006 Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 333:1149
402. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G 2004 Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110:674-678
403. Kinoshita M, Matsumura S, Sueyoshi K, Ogawa S, Fukuda K 2007 Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? Circ J 71:1225-1228
404. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G 2007 Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49:1272-1278
405. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A 2009 Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 54:2157-2163
406. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A 2009 Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54:558-565
407. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC 2005 Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171-178
408. Geluk CA, Asselbergs FW, Hillege HL, Bakker SJ, de Jong PE, Zijlstra F, van Gilst WH 2005 Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 26:1314-1320
409. Sandhu S, Wiebe N, Fried LF, Tonelli M 2006 Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006-2016
410. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT 2006 The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 21:3106-3114
411. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM 2006 Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97:1602-1606
412. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD 2001 Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115-121
413. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N 2004 Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021
414. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G 2006 Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114:1455-1461
415. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC, Jr., Beshai JF, Langberg JJ 2006 Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3:881-886
416. Blanchard L, Collard CD 2007 Non-antiarrhythmic agents for prevention of postoperative atrial fibrillation: role of statins. Curr Opin Anaesthesiol 20:53-56
417. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS 2007 Do statins have an antiarrhythmic activity? Cardiovasc Res 75:10-20
418. Ramani G, Zahid M, Good CB, Macioce A, Sonel AF 2007 Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 100:404-405
419. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P 2006 Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185:3-7
420. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P 2006 Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 185:78-86
421. Zhou B, Teramukai S, Fukushima M 2007 Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 23:194-201
422. McGuinness B, Craig D, Bullock R, Passmore P 2009 Statins for the prevention of dementia. Cochrane Database Syst Rev:CD003160
423. ACCCORD-Study-Group Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med Published electronically March 18, 2010
424. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U 1996 Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853
425. 2000 Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27
426. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
427. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. 1987 Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245
428. Meade T, Zuhrie R, Cook C, Cooper J 2002 Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 325:1139
429. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
430. 1975 Clofibrate and niacin in coronary heart disease. JAMA 231:360-381
431. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W 1986 Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8:1245-1255
432. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592
433. 1999 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354:447-455
434. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F 2002 Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897-1903
435. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122:2152-2159
436. Kromhout D, Giltay EJ, Geleijnse JM n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363:2015-2026
437. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 341:c6273
438. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G 2008 Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1223-1230
439. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K 2007 Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098
440. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K 2008 Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39:2052-2058
441. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y 2009 Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 73:1283-1290
442. Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 74:1451-1457
443. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K 2008 Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200:135-140
444. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K 2009 Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 206:535-539
445. Daida H, Kuwabara Y, Yokoi H, Nishikawa H, Takatsu F, Nakata Y, Kutsumi Y, Oshima S, Nishiyama S, Ishiwata S, Kato K, Nishimura S, Miyauchi K, Kanoh T, Yamaguchi H 2000 Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol 86:550-552, A559
446. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J 2002 Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39:610-616
447. Sawayama Y, Maeda S, Ohnishi H, Okada K, Hayashi J 2006 Effect of probucol on elderly hypercholesterolemic patients in the FAST study. Fukuoka Igaku Zasshi 97:15-24
448. Yadav D, Pitchumoni CS 2003 Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 36:54-62
449. Toskes PP 1990 Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 19:783-791
450. Hofbauer B, Friess H, Weber A, Baczako K, Kisling P, Schilling M, Uhl W, Dervenis C, Buchler MW 1996 Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Gut 38:753-758
451. Iskandar SB, Olive KE 2004 Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci 328:290-294
452. Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A, Vasilakis N, Lambropoulos S 2006 Management of acute severe hyperlipidemic pancreatitis. Digestion 73:259-264
453. Kyriakidis AV, Karydakis P, Neofytou N, Pyrgioti M, Vasilakakis D, Digenis P, Antsaklis G 2005 Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: report of 5 cases. Pancreatology 5:201-204
454. Gan SI, Edwards AL, Symonds CJ, Beck PL 2006 Hypertriglyceridemia-induced pancreatitis: A case-based review. World J Gastroenterol 12:7197-7202
455. Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, Eugenidis NP 2002 Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 34:472-475
456. Lechleitner M, Ladner E, Seyr M, Hoppichler F, Foger B, Hackl JM 1994 [Hypertriglyceridemia and acute pancreatitis]. Acta Med Austriaca 21:125-128
457. Berger Z, Quera R, Poniachik J, Oksenberg D, Guerrero J 2001 [heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia. Experience of 5 cases]. Rev Med Chil 129:1373-1378
458. Jabbar MA, Zuhri-Yafi MI, Larrea J 1998 Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 17:458-461
459. Monga A, Arora A, Makkar RP, Gupta AK 2003 Hypertriglyceridemia-induced acute pancreatitis--treatment with heparin and insulin. Indian J Gastroenterol 22:102-103
460. Henzen C, Rock M, Schnieper C, Heer K 1999 [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis]. Schweiz Med Wochenschr 129:1242-1248
461. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG 2001 Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 138:206-213
462. Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A 1994 Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 35:229-238
463. Yeh JH, Chen JH, Chiu HC 2003 Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher 18:181-185
464. Deleplanque P, Alcalay D, Rouffineau J, Pourrat O, Carretier M, Descoins P, Barbier J 1988 [Major hypertriglyceridemia, associated with severe acute pancreatitis, successfully treated with plasma exchange]. Ann Med Interne (Paris) 139 Suppl 1:86-87
465. Marinella M 1999 Case in point. Abdominal pain secondary to hypertriglyceridemia. Hosp Pract (Minneap) 34:48
466. Ford P, Breheny F, Jenkins I 1998 Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia. Anaesth Intensive Care 26:598
467. Routy JP, Smith GH, Blank DW, Gilfix BM 2001 Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia. J Clin Apher 16:157-159
468. Furuya T, Komatsu M, Takahashi K, Hashimoto N, Hashizume T, Wajima N, Kubota M, Itoh S, Soeno T, Suzuki K, Enzan K, Matsuo S 2002 Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases. Ther Apher 6:454-458
469. Lennertz A, Parhofer KG, Samtleben W, Bosch T 1999 Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 3:227-233
470. Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B 1996 Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 13:96-99
471. Stein JH, Rosenson RS 1998 Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 137:401-405
472. Heaney AP, Sharer N, Rameh B, Braganza JM, Durrington PN 1999 Prevention of recurrent pancreatitis in familial lipoprotein lipase deficiency with high-dose antioxidant therapy. J Clin Endocrinol Metab 84:1203-1205
473. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D 2005 Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330-341
474. Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
475. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF 1989 The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9:297-301
476. Kinirons MT, O'Mahony MS 2004 Drug metabolism and ageing. Br J Clin Pharmacol 57:540-544
477. Gupta S 1995 P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 7:19-29
478. Williams FM, Wynne H, Woodhouse KW, Rawlins MD 1989 Plasma aspirin esterase: the influence of old age and frailty. Age Ageing 18:39-42
479. Hodel C 2002 Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159-168
480. Baker SK 2005 Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31:572-580
481. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, Sawanobori K, Kitahara M, Kodama T, Saito Y 2006 Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. J Atheroscler Thromb 13:295-307
482. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD 2005 Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 25:2560-2566
483. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD 2002 Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
484. Neal RC, Ferdinand KC, Ycas J, Miller E 2009 Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 122:73-78
485. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR 2006 Statin-related adverse events: a meta-analysis. Clin Ther 28:26-35
486. McClure DL, Valuck RJ, Glanz M, Hokanson JE 2007 Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 16:132-143
487. Davidson MH 2004 Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 3:547-557
488. Waters DD 2005 Safety of high-dose atorvastatin therapy. Am J Cardiol 96:69F-75F
489. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH 2005 Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165:2671-2676
490. Thompson PD, Clarkson P, Karas RH 2003 Statin-associated myopathy. JAMA 289:1681-1690
491. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA 2003 Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553-564
492. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH 2006 Statin safety: an assessment using an administrative claims database. Am J Cardiol 97:61C-68C
493. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH 2007 Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50:409-418
494. Chalasani N 2005 Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41:690-695
495. McKenney JM, Proctor JD, Harris S, Chinchili VM 1994 A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-677
496. Caroli-Bosc FX, Le Gall P, Pugliese P, Delabre B, Caroli-Bosc C, Demarquay JF, Delmont JP, Rampal P, Montet JC 2001 Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 46:540-544
497. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH 2001 Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 56:931-933
498. Yang CC, Jick SS, Jick H 2003 Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 163:1926-1932
499. 1978 A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40:1069-1118
500. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G 2005 Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192
501. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S 2007 Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27-33
502. Bottorff MB 2006 Statin safety and drug interactions: clinical implications. Am J Cardiol 97:27C-31C
503. Mousa O, Brater DC, Sunblad KJ, Hall SD 2000 The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 67:267-274
504. Stern R, Abel R, Gibson GL, Besserer J 1997 Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 37:1062-1064
505. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG 2003 Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89:417-421
506. Ko DT, Mamdani M, Alter DA 2004 Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291:1864-1870
507. Jackevicius CA, Mamdani M, Tu JV 2002 Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467
508. McGowan MP 2004 There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 110:2333-2335
509. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM 2006 Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol 98:923-928
510. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ 2005 Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611-616
511. Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P, Chretin S, Yin D, Alemao E, de Pouvourville G 2006 Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 185:58-64
512. Rasmussen JN, Chong A, Alter DA 2007 Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297:177-186
513. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB 2006 The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 61:1059-1064
514. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS 2006 Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 6:48
515. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S 2007 Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63:698-708
516. Fonarow GC 2005 In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits. Chest 128:3641-3651
517. Bailey TC, Noirot LA, Blickensderfer A, Rachmiel E, Schaiff R, Kessels A, Braverman A, Goldberg A, Waterman B, Dunagan WC 2007 An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 167:586-590
518. Naughton C, Feely J, Bennett K 2007 A clustered randomized trial of the effects of feedback using academic detailing compared to postal bulletin on prescribing of preventative cardiovascular therapy. Fam Pract
519. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA 2006 Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 12 Spec no.:SP11-19
520. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH 2007 Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect. Am J Epidemiol 166:348-354
521. Parris ES, Lawrence DB, Mohn LA, Long LB 2005 Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 28:595-599
522. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J 2006 Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 19:46-53
523. Maki KC, Galant R, Davidson MH 2005 Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 96:59K-64K; discussion 34K-35K
524. Lozano JV, Pallares V, Cea-Calvo L, Llisterri JL, Fernandez-Perez C, Marti-Canales JC, Aznar J, Gil-Guillen V, Redon J 2008 Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin 24:659-670
525. Fantin F, Di Francesco V, Rossi A, Giuliano K, Marino F, Cazzadori M, Gozzoli MP, Vivian ME, Bosello O, Rajkumar C, Zamboni M Abdominal obesity and subclinical vascular damage in the elderly. J Hypertens 28:333-339
526. Bang OY, Saver JL, Liebeskind DS, Pineda S, Ovbiagele B 2008 Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 70:841-847
527. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G 2002 Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106:2537-2542
528. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M 1997 Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359
529. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM 2005 Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 28:1916-1921
530. Farwell WR, Sesso HD, Buring JE, Gaziano JM 2005 Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol 96:1129-1134
531. Liu J, Joshi D, Sempos CT 2009 Non-high-density-lipoprotein cholesterol and cardiovascular risk factors among adolescents with and without impaired fasting glucose. Appl Physiol Nutr Metab 34:136-142
532. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT 2009 Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55:35-41
533. Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P 2009 Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis 202:289-295
534. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE 2005 Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294:326-333
535. Schulze MB, Shai I, Manson JE, Li T, Rifai N, Jiang R, Hu FB 2004 Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia 47:2129-2136
536. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB 2005 Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112:3375-3383
537. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL 2001 Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161:1413-1419
538. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ 1998 Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453-1460
539. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV 2003 Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26:16-23
540. Rallidis LS, Pitsavos C, Panagiotakos DB, Sinos L, Stefanadis C, Kremastinos DT 2005 Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals. Atherosclerosis 179:305-309
541. Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K, Curb JD 2005 Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 25:1718-1722
542. Nakamura T, Obata JE, Takano H, Kawabata K, Sano K, Kobayashi T, Fujioka D, Saito Y, Yano T, Kugiyama K 2009 High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 202:234-240
543. Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW 2002 Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25:989-994
544. Kappelle PJ, Dallinga-Thie GM, Dullaart RP Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim Biophys Acta 1801:89-94
545. Langsted A, Freiberg JJ, Nordestgaard BG 2008 Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047-2056
546. Dungan KM, Guster T, DeWalt DA, Buse JB 2007 A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin 23:2689-2695
547. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M 2005 Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 45:1067-1072
548. Blake GJ, Otvos JD, Rifai N, Ridker PM 2002 Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106:1930-1937
549. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R 2002 Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22:1175-1180
550. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ 2006 Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113:1556-1563
551. Rosenson RS, Otvos JD, Freedman DS 2002 Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90:89-94
552. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, Jr., O'Leary DH, Saad MF, Tsai MY, Sharrett AR 2007 LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192:211-217
553. Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella M, Garvey WT 2006 Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med 23:955-966
554. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL 2003 Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 64:817-828
555. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO, Jr. 1982 Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 97:833-839
556. Walldius G, Jungner I, Kolar W, Holme I, Steiner E 1992 High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein related MOrtality RISk) study. Blood Press Suppl 4:35-42
557. Holme I, Aastveit AH, Jungner I, Walldius G 2008 Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 264:30-38
558. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952
559. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B 2003 Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91:1173-1177
560. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J 2005 Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179:339-344
561. Keulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW 2002 Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 22:283-288
562. Lind L 2007 Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 190:378-384
563. Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD 2008 Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 57:3289-3296
564. Corsetti JP, Zareba W, Moss AJ, Sparks CE 2004 Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 177:367-373
565. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, Walldius G, Hellenius ML, Hamsten A 2009 Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 30:710-717
566. Hsia SH, Pan D, Berookim P, Lee ML 2006 A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 98:1047-1052
567. Stein EA, Sniderman A, Laskarzewski P 2005 Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96:36K-43K; discussion 34K-35K
568. Grundy SM 2002 Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106:2526-2529
569. Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW 2008 ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients. Curr Med Res Opin 24:359-364
570. Ballantyne CM, Raichlen JS, Cain VA 2008 Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 52:626-632
571. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D 2004 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173:381-391
572. LSE http://www.policy-centre.com/downloads/European-Cholesterol-Guidelines07.pdf.
573. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S 2006 Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22:913-927
574. Shimano H, Arai H, Harada-Shiba M, Ueshima H, Ohta T, Yamashita S, Gotoda T, Kiyohara Y, Hayashi T, Kobayashi J, Shimamoto K, Bujo H, Ishibashi S, Shirai K, Oikawa S, Saito Y, Yamada N 2008 Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 15:116-121
575. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM 2006 Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259:247-258
576. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL 2008 Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31:811-822
577. ADA Standards of medical care in diabetes--2010. Diabetes Care 33 Suppl 1:S11-61
578. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR 2009 Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 55:407-419
579. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW 2005 Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 95:360-366
580. FDA http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm.
581. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP 2002 Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162:1568-1576
582. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E 2006 Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114:281-288
583. Bays HE, Cohen DE 2007 Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 23:1673-1684
584. Lin YL, Wang TH, Lee MH, Su NW 2008 Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol 77:965-973
585. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB 2001 Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585-1591
586. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM, Jr. 2005 A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142:95-104